Key data
| Regulation | Council Decision (EU) 2026/1966, of 27 August 2026 |
|---|---|
| Publication | 2 September 2026 |
| Entry into force | 27 August 2026 |
| Affected parties | EU Member States, health authorities and sectors with international activity |
| Category | European Regulation |
| Official reference | OJ:L_202601966 |
| Base regulatory framework | International Health Regulations (IHR 2005) |
Companies with international operations in the health, pharmaceutical and transport sectors have a new mandatory reference framework. Council Decision (EU) 2026/1966, adopted on 27 August 2026 and published in the Official Journal on 2 September, sets the position that the European Union will defend on behalf of all its Member States at the first meeting of the Committee of States Parties for the Implementation of the International Health Regulations (IHR 2005).
This is not a minor procedural change. The IHR 2005 is the international legal instrument that determines how countries—and by extension companies operating in them—must prevent, detect and respond to public health emergencies of international concern. The EU's unified position in this multilateral forum has direct consequences for the protocols that companies must have in place.
What does this regulation establish?
The Council decision establishes three key elements:
- European negotiating mandate: The EU speaks with a single voice in the Committee of States Parties to the IHR 2005, ensuring consistency in the positions adopted by the 27 Member States.
- Cross-border health coordination framework: Joint response mechanisms for public health emergencies of international concern are strengthened, including early warning systems.
- Notification obligations: States—and economic operators subject to their jurisdiction—are bound by the notification protocols agreed in the Committee.
The IHR 2005, on which this entire decision pivots, is the international treaty of the World Health Organization (WHO) that regulates the global response to health emergencies. Its implementation affects ports, airports, border crossings and all operators managing people, goods or services in contexts of international health risk.
| Element | Content |
|---|---|
| Base instrument | International Health Regulations (IHR 2005) |
| Implementation forum | Committee of States Parties for the Implementation of the IHR |
| Target meeting | First meeting of the Committee |
| Coordination scope | Cross-border health responses, early warning systems, notification obligations |
| Sectors with operational impact | Health, pharmaceutical, international transport |
Economic and operational impact
For companies, this decision does not generate immediate direct costs, but it does consolidate a regulatory framework that can activate costly operational obligations in the event of an international health emergency. The concrete impacts are:
- Pharmaceutical sector: Greater requirements for traceability and supply protocols during emergencies. Companies distributing medicines internationally must have contingency plans aligned with IHR 2005.
- International transport: Airlines, shipping companies and logistics operators are subject to the notification and health control protocols that emerge from Committee agreements. This can translate into additional operational costs during health alerts.
- Health sector: Hospitals, clinics and health service providers with cross-border activity must adapt their alert and notification systems to the standards strengthened by this Committee.
- Companies with global supply chains: Any company that depends on suppliers or markets in countries affected by an international health emergency may see its operations interrupted if it does not have documented response protocols.
The cost of not being prepared is not measured in immediate fines, but in the ability to maintain operations during a global health crisis. Companies that already suffered disruptions during the COVID-19 pandemic know this risk well.
Who does it affect?
- Health and hospital sector companies with international activity or suppliers
- Pharmaceutical laboratories and medicine distributors with global supply chains
- International transport operators: airlines, shipping companies, logistics and courier companies
- Health authorities of the 27 EU Member States
- Port, airport and border crossing managers
- Companies importing and exporting products with health implications
- Consultancies and advisory firms providing services to the above sectors
Practical example
A Spanish pharmaceutical company that distributes medicines in several EU countries and maintains supply agreements with manufacturers in Asia operates under the IHR 2005 framework whenever a public health emergency of international concern is declared.
With the unified position that the EU will defend in the Committee, the notification and response protocols agreed at that first meeting will be transferred uniformly to all Member States. This means the company will not have to manage 27 different regulatory frameworks, but just one: the one that emerges from the agreed European position.
The concrete action this company should take now is to review its international health crisis management plan and ensure it includes the notification mechanisms required by IHR 2005, anticipating the agreements to be adopted at the Committee's first meeting.
What should companies do now?
- Identify exposure to IHR 2005: Determine whether your company operates in sectors or with supply chains that fall within the scope of the International Health Regulations (health, pharma, international transport, logistics).
- Review health contingency plans: Update or create a response protocol for international public health emergencies that includes notification mechanisms aligned with IHR 2005.
- Monitor Committee agreements: Follow the results of the first meeting of the Committee of States Parties, as the agreements adopted will translate into concrete obligations for economic operators.
- Coordinate with national health authorities: Establish communication channels with the competent authorities of your Member State to receive early alerts and operational guidance in case of emergency.
- Specialized advice: If your company has operations in multiple countries, consult with a specialist in international health law to assess the specific impact of Committee agreements on your operations.
Frequently asked questions
What is the International Health Regulations (IHR 2005) and why does it affect my company?
The IHR 2005 is the WHO's international treaty that regulates how countries must prevent, detect and respond to public health emergencies of international concern. It affects companies in the health, pharmaceutical and international transport sectors because it establishes notification protocols, health controls at borders and response obligations that economic operators must comply with during a global health emergency.
What changes with Decision (EU) 2026/1966 compared to the previous situation?
The decision establishes that the EU will act with a unified position at the first meeting of the Committee of States Parties to the IHR 2005. This means that the 27 Member States will defend a common negotiating mandate, ensuring consistency in the cross-border health response protocols agreed. For companies, this implies greater regulatory uniformity across the EU in matters of international health emergencies.
When does this decision enter into force and what timeline do companies have to adapt?
Decision (EU) 2026/1966 entered into force on 27 August 2026, the date of its adoption by the Council. It was published in the Official Journal on 2 September 2026. It does not establish a specific adaptation timeline for companies, but the agreements adopted at the first meeting of the Committee of States Parties will generate concrete obligations that operators must implement.
Which business sectors face the greatest operational risk from this regulation?
The sectors with the greatest exposure are three: the pharmaceutical sector (distribution and supply of medicines at international level), international transport (airlines, shipping companies and logistics operators subject to health controls at borders) and the health sector (hospitals and providers with cross-border activity). Companies with global supply chains that depend on suppliers in areas with health risk are also affected.
Where can I consult the EU's official position and the IHR Committee agreements?
The EU's official position is set out in Decision (EU) 2026/1966, published in the Official Journal of the EU with reference OJ:L_202601966. The agreements adopted at the first meeting of the Committee of States Parties will be published through the WHO's official channels and will be communicated to Member States through their national health authorities.
Official source
View complete regulation at official source
Disclaimer: This article is for informational purposes only and does not constitute legal advice. For specific decisions, consult a qualified professional. Source: https://eur-lex.europa.eu/./legal-content/AUTO/?uri=OJ:L_202601966
